RBC Canadian Discount Bond Fund (RCDB)

Overview

Medicenna Therapeutics Corp. is a pioneering immunotherapy company that focuses on the creation and commercialization of advanced therapeutics called Superkines and empowered Superkines. These innovative treatments are designed to combat cancer and various other diseases by leveraging the body's immune system. Headquartered in Toronto, Canada, the company is at the forefront of developing a robust pipeline of potential therapies that aim to address the unmet needs of patients with cancer and autoimmune diseases.

Products and Services

Medicenna Therapeutics Corp. has developed a range of novel therapeutics, each targeting different aspects of cancer treatment and immunoregulation. These include:

• bizaxofusp (MDNA55): This is a pioneering treatment for recurrent glioblastoma, a type of brain tumor. Bizaxofusp is an engineered cytokine that specifically targets the interleukin-4 (IL-4) receptor, making it a targeted therapy for patients with this aggressive cancer.
• MDNA11: An enhanced version of interleukin-2 (IL-2), MDNA11 is designed to activate and proliferate immune cells necessary to fight cancer effectively. This therapy represents a next-generation approach to harnessing the body's natural defense mechanisms.
• MDNA209: This compound is an IL-2 antagonist developed for the treatment of autoimmune diseases, such as multiple sclerosis and graft versus host disease (GVHD). By blocking the action of IL-2, MDNA209 aims to mitigate the immune system's overactivity that characterizes these conditions.
• MDNA413: A dual IL-4/IL-13 antagonist, this drug is aimed at cancer immunotherapies. By targeting these two cytokines, MDNA413 is designed to overcome the immunosuppressive tumor microenvironment, enhancing the effectiveness of cancer treatments.
• MDNA113: This novel therapy is a masked bi-functional anti-PD1-IL2 Superkine designed for the treatment of various solid tumors. Combining PD-1 inhibition with IL-2 activation offers a multifaceted approach to stimulating an anti-tumor immune response.
• MDNA132: An interleukin-13 (IL-13) Superkine, MDNA132 targets tumors by exploiting the IL-13 receptor's role in cancer biology. This treatment is being developed for various tumor types, leveraging the unique characteristics of IL-13 in tumor microenvironments.

In addition, Medicenna's BiSKITs platform highlights its innovative approach by developing designer Superkines. This platform allows for the fusion of Superkines with other proteins, inhibitors, antibodies, cytokines, or Superkines to create highly targeted and effective therapies for a range of diseases.